Faron Pharmaceutical Ltd.

Faron Pharmaceutical Ltd. is a privately owned clinical stage drug discovery and development company in Turku, Finland. Today Faron has three major drug development projects focusing on acute trauma, inflammatory diseases, and cancer/metastasis growth. Faron’s lead product FP-1201 has recently passed successfully a phase I/II trial in the UK to treat vascular leakage in ALI/ARDS patients. Faron is currently expanding the FP-1201-lyo program to a pan-European pivotal phase III trial that company hopes to get started in 2013. The primary efficacy endpoint in this trial will be the all cause mortality at day 28, the only accepted primary end point for marketing approval by EMA.



henkilo_faron.jpg Markku Jalkanen